For research use only. Not for therapeutic Use.
ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively[1].
ZK824190 (2 mg/kg; PO; Rats with EAE model) exhibits a relatively high oral availability and a moderate half time (T1/2=2.8 h)[1].
| Catalog Number | I043926 |
| CAS Number | 2629177-12-2 |
| Synonyms | (2R)-2-[6-[3-[3-(aminomethyl)phenyl]phenoxy]-3,5-difluoropyridin-2-yl]oxybutanoic acid;hydrochloride |
| Molecular Formula | C22H21ClF2N2O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H20F2N2O4.ClH/c1-2-19(22(27)28)30-21-18(24)11-17(23)20(26-21)29-16-8-4-7-15(10-16)14-6-3-5-13(9-14)12-25;/h3-11,19H,2,12,25H2,1H3,(H,27,28);1H/t19-;/m1./s1 |
| InChIKey | IXYNABONTFZVBF-FSRHSHDFSA-N |
| SMILES | CCC(C(=O)O)OC1=C(C=C(C(=N1)OC2=CC=CC(=C2)C3=CC=CC(=C3)CN)F)F.Cl |
| Reference | [1]. Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. |
